Indolent and mantle-cell non-Hodgkin lymphoma - Clinical

 
Meletios Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
 
The authors of the abstract conclude: 
ASPEN is the largest phase 3 trial of BTK inhibitors in WM and the first head-to-head comparison of BTK inhibitors in any disease. Although not statistically significant, ZANU was associated with a higher CR+VGPR response rate, and demonstrated clinically meaningful advantages in safety and tolerability compared with IBR. ClinicalTrials.gov: NCT03053440.
 
————————————————————————————————————————————————————————
 
 
M.J. Kersten, Monique Minnema, Karima Amaador, et al.
 
The authors of the abstract conclude: 
Treatment with IRD is feasible and easy to administer and shows promising efficacy with manageable toxicity in patients with relapsed WM. By central review, a more prominent decrease was observed for B-cells than for the plasma cell component in the bone marrow.
————————————————————————————————————————————————————————
 
 
Alexandra Albertsson Lindblad, Thorgerdur Palsdottir, Ingrid Glimelius, et al.
 
The authors of the abstract conclude: 
This population-based study on long-term survival in an unselected national cohort of MCL patients supports the use of R-bendamustine or intensified immunochemotherapy with HD-AHCT upfront (such as MCL2) over R-CHOP/CHOEP. Future real-world analyses incorporating data on comorbidity, molecular characteristics of the disease and treatment strategies at relapse is needed, together with continuous evaluation of novel strategies, for a deeper understanding of prognosis in MCL and to improve outcome in these patients.
————————————————————————————————————————————————————————
 
 
Steven Le Gouill*1, 2, Franck Morschhauser3, Krimo Boua, et al
 
The authors of the abstract conclude: 
Ibrutinib/Venetoclax/Obinutuzumab combination therapy has a very good safety profile and shows high efficacity rates at the molecular level in untreated patients. Oasis step C is the first trial that report the use of Ibrutinib/Venetoclax/Obinutuzumab as frontline therapy in MCL.
————————————————————————————————————————————————————————
 
 
Chiara Rusconi, Chan Y. Cheah, David Tucker, et al.
 
The authors of the abstract conclude: 
This is the first large cohort analyzing outcome of pts treated with ibrutinib for CNS relapse of MCL. With the usual limitations of a retrospective analysis, ibrutinib was associated with an improved response and survival compared to standard immuno-CHT in this difficult to treat population, with half of pts alive at 1 year.